Literature DB >> 10576123

Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature.

K Ahlfors1, S A Ivarsson, S Harris.   

Abstract

This report summarizes knowledge accumulated in a long-term study of congenital and maternal cytomegalovirus (CMV) infection in Sweden. Some new findings are included. We considered diagnostic methods, sources of maternal infection (including occupational risks), roles of primary and secondary maternal infections, transmission to foetuses, incidence, symptoms and prognosis of established congenital infection and relative importance of such infection in infantile sensorineural deafness, microcephaly and type 1 diabetes mellitus. Virus isolation testing was done 1977-1985 on 16,474 newborns. 76 (0.5%) congenitally infected infants were found, 22/76 (29%) with transient neonatal symptoms and 11/60 (18%) with neurological symptoms by the age of 7 y. Type of maternal CMV infection was serologically determined in 62/76 cases (30 primary, 32 secondary). CNS disturbances in the infants occurred after both primary (all trimesters) and secondary maternal infections. The negative potential of secondary maternal infections might be an obstacle to preventive vaccination.

Entities:  

Mesh:

Year:  1999        PMID: 10576123     DOI: 10.1080/00365549950163969

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  59 in total

1.  Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines.

Authors:  Mark R Schleiss
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission?

Authors:  Mark R Schleiss
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

3.  Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection.

Authors:  Soren Gantt; Arnaud Marchant; Suresh B Boppana
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

Review 4.  Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection.

Authors:  Michael J Cannon; Terri B Hyde; D Scott Schmid
Journal:  Rev Med Virol       Date:  2011-06-15       Impact factor: 6.989

5.  Human cytomegalovirus (HCMV) and hearing impairment: infection of fibroblast cells with HCMV induces chromosome breaks at 1q23.3, between loci DFNA7 and DFNA49 -- both involved in dominantly inherited, sensorineural, hearing impairment.

Authors:  Mona Nystad; Toril Fagerheim; Vigdis Brox; Elizabeth A Fortunato; Øivind Nilssen
Journal:  Mutat Res       Date:  2007-07-25       Impact factor: 2.433

6.  Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection.

Authors:  A Mackenzie Dreher; Nitin Arora; Karen B Fowler; Zdenek Novak; William J Britt; Suresh B Boppana; Shannon A Ross
Journal:  J Pediatr       Date:  2014-01-14       Impact factor: 4.406

7.  Routine Screening for Rubella and CMV Antibodies During Pregnancy: Is it Justifiable?

Authors:  Anita Chakravarti; Abha Sharma; Monika Matlani
Journal:  J Obstet Gynaecol India       Date:  2013-07-12

8.  Clinical and radiologic evaluation of cytomegalovirus-induced thrombocytopenia in infants between 1 and 6 months of age.

Authors:  Joon-Won Kang; Gee-Na Kim; Sun-Young Kim; Hee-Jin Kim; Eun-Sil Park; Jae-Young Kim; Young-Ho Lee
Journal:  Korean J Hematol       Date:  2010-03-31

9.  Neonatal cytomegalovirus infection: diagnostic modalities available for early disease detection.

Authors:  Prateek Bhatia; A Narang; Ranjana W Minz
Journal:  Indian J Pediatr       Date:  2010-01       Impact factor: 1.967

10.  Trends in hospitalizations for diagnosed congenital cytomegalovirus in infants and children in Australia.

Authors:  Holly Seale; Robert Booy; C Raina MacIntyre
Journal:  BMC Pediatr       Date:  2009-01-26       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.